The Top 5 Biosimilar Articles for the Week of June 9

Number 5: Leading biosimilar companies Sandoz, STADA Arzneimittel, and Samsung Bioepis report impressive Q1 2025 growth, driven by strong denosumab biosimilars and expanding portfolios.

Number 4: Biosimilar associations advocate for lower development costs and streamlined regulations to enhance patient access to affordable biosimilars.

Number 3: Denosumab biosimilars Wyost and Jubbonti launch in the US, enhancing access to affordable treatments for osteoporosis and cancer-related skeletal events.

Number 2: Patent settlements accelerate the entry of generics and biosimilars, saving the health care system $422.9 billion and enhancing drug accessibility.

Number 1: New research confirms denosumab biosimilar SB16 matches Prolia in efficacy, offering a cost-effective treatment option for postmenopausal osteoporosis.

To read all of these articles and more, visit centerforbiosimilars.com.